View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
November 19, 2012

Ventus launches obstructive sleep apnoea treatment in Canada

Ventus Medical has announced the availability of a non-invasive treatment for mild, moderate and severe obstructive sleep apnoea (OSA) in Ontario, Canada.

By admin-demo

Ventus Medical has announced the availability of a non-invasive treatment for mild, moderate and severe obstructive sleep apnoea (OSA) in Ontario, Canada.

Provent sleep apnoea therapy features a MicroValve design which is placed over the nostrils and secured with hypoallergenic adhesive.

"The company said its Provent therapy will be made available throughout Canada in June 2013 by its distribution partner, ioSleep."

Using nasal expiratory positive airway pressure (EPAP), the therapy keeps the patient’s airway open during sleep, which otherwise will collapse and lead to fatigue, early morning headaches, irritability, depression, learning and memory difficulties and sexual dysfunction.

Recent studies have also shown that OSA is associated with high blood pressure, irregular heartbeat, heart attack, strokes and diabetes, according to the company.

Ventus Medical chief medical officer Philip Westbrook said the company believes that the clinically-proven Provent therapy is an alternative to continuous positive airway pressure treatment used for the large number of people affected by OSA in Canada.

"Provent has been used effectively in the United States since 2008 and in clinical studies, Provent therapy improved quality of sleep while it reduced apnoea (breathing disruptions), daytime sleepiness and snoring," Westbrook added.

"Importantly, Provent is easy to use, portable and discreet for use at home or when travelling."

Ventus Medical president and chief executive officer Peter Wyles said: "As we look at global market opportunities for Provent therapy, Canada fits directly into our corporate strategy, which is to target markets where three factors come together: high prevalence of OSA, acceptance of innovative therapies and importantly, a need for new therapeutic options that address low patient compliance."

The company said its Provent therapy will be made available throughout Canada in June 2013 by its distribution partner, ioSleep.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network